

## **Pediatric Thoracic Transplant Recipient Follow-Up Worksheet**

FORM APPROVED: O.M.B. NO. 0915-0157 Expiration Date: 10/31/2010

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI<sup>®</sup> application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI<sup>®</sup> application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information	
Name:	DOB:
SSN:	Gender:
HIC:	Tx Date:
Previous Follow-Up:	Previous Px Stat Date:
rollow op.	otal bate.
Transplant Discharge Date:	
State of Permanent Residence:*	
Zip Code:★	-
B. H. I. C	
Provider Information	
Recipient Center:	
Followup Center:	
Physician Name: *	
NPI#:★	
	C Transplant Center
Follow-up Care Provided By:*	Non Transplant Center Specialty Physician
	Primary Care Physician
	C Other Specify
Specify:	
ореспу.	
Donor Information	
UNOS Donor ID #:	
Donor Type:	

Patient Status	
Date: Last Seen, Retransplanted or Death <del>*</del>	
	LIVING
Patient Status:*	© DEAD
	© RETRANSPLANTED
Primary Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Hospitalizations:	
Has the patient been hospitalized since the last patient status date: ★	C YES ONO UNK
Number of Hospitalizations:	ST=
Hospitalized for Rejection:	C YES C NO C UNK
Hospitalized for Infection:	C YES NO UNK
Noncompliance:	
Was there evidence of noncompliance with immunosuppression medication during this follow-up period that compromised the patient's recovery:	C YES NO UNK
Functional Status: *	

Cognitive Development: ★	C Definite Cognitive delay/impairment
	Probable Cognitive delay/impairment
	Questionable Cognitive delay/impairment
	No Cognitive delay/impairment
	Not Assessed
	O Definite Motor delay/impairment
	Probable Motor delay/impairment
Motor Development: <b></b> ★	<ul> <li>Questionable Motor delay/impairment</li> </ul>
	No Motor delay/impairment
	Not Assessed
	Within One Grade Level of Peers
Academic Progress: *	O Delayed Grade Level
	Special Education
	Not Applicable < 5 years old/ High School graduate or GED
	Status Unknown
	Full academic load
	C Reduced academic load
	Unable to participate in academics due to disease or condition
	Not Applicable < 5 years old/ High School graduate or GED
	C Status Unknown
Primary Insurance at Follow-up: *	
rimary insurance at rollow-up:	

Specify	
Clinical Information	
Date of Measurement:	
Height: <b>*</b>	ft. in. cm ST=
Weight: *	lbs. kg <b>ST=</b>
вмі:	kg/m <sup>2</sup>
Graft Status:*	Functioning Failed
If death is indicated for the recipient, select Functioning.	and the death was a result of some other factor unrelated to graft failure
Date of Graft Failure:	
	Primary Non-Function
	C Acute Rejection
Primary Cause of Graft Failu	
	Other, Specify
	Other, Specify
Other, Specify:	
Graft Function:	
Lung:	
FeV1: *	% ST=
O2 Requirement at Rest: ★	L/min ST=
	○ NO BOS
Describing Of Process	C Yes, Grade 1
Bronchiolitis Obliterans Syndrome: **	C Yes, Grade 2
	Yes, Grade 3
	Yes, Grade UNK
	- roof ended entit

	Unknown
Bronchial Stricture (Since last follow-up): ★	C YES C NO C
If yes, Stent:	YES NO CUNK
Post Transplant Events:	
Drug Treated Hypertension:	C YES O NO C UNK
Bone Disease (Symptomatic):	C YES C NO C UNK
Chronic Liver Disease:	C YES C NO C UNK
Cataracts:	C YES C NO C UNK
Diabetes onset during the follow-up period: ★	C YES C NO C UNK
Diabetes: If Yes, Insulin Dependent:	C YES C NO C UNK
Renal Dysfunction: *	C YES O NO C UNK
If Yes, Creatinine > 2.5 mg/dl:	C YES O NO O UNK
Chronic Dialysis:	C YES ONO UNK
Renal Tx since Thoracic Tx:	C YES O NO C UNK
Stroke:	C YES C NO C UNK
Drug Treated Hyperlipidemia:	C YES C NO C UNK
Did patient have any acute rejection	Yes, at least one episode treated with anti-rejection agent

episodes during the follow-up period:*	<ul><li>Yes, none treated with additional anti-rejection agent</li><li>No</li></ul>
Was biopsy done to confirm acute rejection:	<ul> <li>Unknown</li> <li>Biopsy not done</li> <li>Yes, rejection confirmed</li> <li>Yes, rejection not confirmed</li> <li>Unknown</li> </ul>
Post Transplant Malignancy: *	C YES C NO C UNK
Donor Related:	C YES C NO C UNK
Recurrence of Pre-Tx Tumor:	C YES C NO C UNK
De Novo Solid Tumor:	C YES C NO C UNK
De Novo Lymphoproliferative disease and Lymphoma:	C YES C NO C UNK
Treatment	
Biological or Anti-viral therapy:	C YES C NO C Unknown/Cannot disclose

Acyclovir (Zovirax)

	☐ Cytogam (CMV) ☐ Gamimune ☐ Gammagard			
If Yes, check all that apply:	Ganciclovir (Cytovene)  Valgancyclovir (Valcyte)  HBIG (Hepatitis B Immune Globulin)  Flu Vaccine (Influenza Virus)  Lamivudine (Epivir) (for treatment of Hepatitis B)  Valacyclovir (Valtrex)			
Specify: * Specify:	Other, Specify			
Other therapies:	C YES NO			
If Yes, check all that apply:	<ul><li>☐ Photopheresis</li><li>☐ Plasmapheresis</li><li>☐ Total Lymphoid Irradiation (TLI)</li></ul>			
Immunosuppressive Information				
Previous Validated Maintenance Follow- Up Medications:				
Previous Validated Maintenance Follow- Up Medications:				
Were any medications given during the follow-up period for maintenance:	<ul> <li>Yes, same as validated TRR form</li> <li>Yes, same as previous validated report</li> <li>Yes, but different than previous validated report</li> </ul>			

	None given
Did the physician discontinue all maintenance immunosuppressive medications:	C YES NO
Did the patient participate in any clinical research protocol for immunosuppressive medications:	C YES NO
Specify: *	

## **Immunosuppressive Medications**

**View Immunosuppressive Medications** 

## **Definitions Of Immunosuppressive Follow-Up Medications**

For each of the immunosuppressant medications listed, check **Previous Maintenance (Prev Maint)**, **Current Maintenance (Curr Maint)** or **Anti-rejection (AR)** to indicate all medications that were prescribed for the recipient during this follow-up period, and for what reason. If a medication was not given, leave the associated box(es) blank.

**Previous Maintenance (Prev Maint)** includes all immunosuppressive medications given during the report period, which covers the period from the last clinic visit to the current clinic visit, *for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug* (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

**Current Maintenance (Curr Maint)** includes all immunosuppressive medications given at the current clinic visit to begin in the next report for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

**Anti-rejection (AR)** immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode since the last clinic visit (example: Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

Note: The Anti-rejection field refers to any anti-rejection medications since the last clinic visit, not just at the time of the current clinic visit.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Previous Maint, or Current Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive medications.** 

Prev Curr AR Maint Maint

Steroids (Prednisone,Methylprednisolone,Solumedrol,Medrol,Decadron)				
Atgam (ATG)				
OKT3 (Orthoclone, Muromonab)				
Thymoglobulin				
Simulect - Basiliximab				
Zenapax - Daclizumab				
Azathioprine (AZA, Imuran)				
EON (Generic Cyclosporine)				
Gengraf (Abbott Cyclosporine)				
Other generic Cyclosporine, specify brand:				
Neoral (CyA-NOF)				
Sandimmune (Cyclosporine A)				
CellCept (Mycophenolate Mofetil; MMF)				
Generic MMF (Generic CellCept)				
Prograf (Tacrolimus, FK506)				
Generic Tacrolimus (Generic Prograf)				
Modified Release Tacrolimus FK506E (MR4)				
Sirolimus (RAPA, Rapamycin, Rapamune)				
Myfortic (Mycophenolate Sodium)				
Other Immunosuppressive Medications				
	Prev Maint	Curr Maint	AR	
Campath - Alemtuzumab (anti-CD52)				
Cyclophosphamide (Cytoxan)				
Leflunomide (LFL, Arava)				
Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)	П			

Other Immunosuppressive Medication, Specify			
Rituximab			
Investigational Immunosuppressive Medications			
	Prev Maint	Curr Maint	AR
Everolimus (RAD, Certican)			
Other Immunosuppressive Medication, Specify			
UNOS View Only			
Comments:			

Copyright @ 2010 United Network for Organ Sharing. All rights reserved.

Public Burden/Privacy Act Statements